<DOC>
	<DOCNO>NCT00416832</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill cancer cell . Giving combination chemotherapy together radiation therapy may kill cancer cell . PURPOSE : This phase II trial study side effect well give combination chemotherapy together radiation therapy work treat young patient Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Young Patients With Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety efficacy intensify etoposide administer part OEPA combination chemotherapy ( vincristine , etoposide , prednisone , doxorubicin hydrochloride ) pediatric male patient intermediate advance Hodgkin 's lymphoma ( HL ) . - Determine safety efficacy COPDIC combination chemotherapy ( cyclophosphamide , vincristine , prednisone , dacarbazine ) COPP combination chemotherapy ( cyclophosphamide , vincristine , procarbazine hydrochloride , prednisone ) reduce gonadotoxicity male female patient . - Assess quality assurance regimens pediatric female patient intermediate advanced HL . OUTLINE : This pilot , multicenter study . Patients stratify accord disease stage ( I IIA v IIB , IIE , IIIA v IIBE , IIIBE , IV ) . - Stratum 1 ( stage I IIA ) : Male patient receive vincristine IV day 1 , 8 , 15 , etoposide IV 2 hour day 3-7 , oral prednisone day 1-15 , doxorubicin hydrochloride IV 4 hour day 1 15 ( OEPA ) . Female patient receive vincristine , prednisone , doxorubicin hydrochloride male patient oral procarbazine hydrochloride day 1-15 ( OPPA ) . Both regimen repeat every 4 week 2 course absence disease progression unacceptable toxicity . Patients achieve complete remission undergo involved-field radiotherapy begin 3 week completion chemotherapy . - Stratum 2 ( stage IIB , IIE , IIIA ) : Male patient receive 2 course OEPA stratum 1 follow 2 course COPDIC comprise oral prednisone day 1-15 , dacarbazine IV 30 minute day 1-3 , vincristine IV cyclophosphamide IV 1 hour day 1 8 . Female patient receive 2 course OPPA stratum 1 follow COPP comprise oral prednisone 2 course oral procarbazine hydrochloride day 1-15 vincristine IV cyclophosphamide IV 1 hour day 1 8 . Both regimen repeat every 4 week 2 course absence disease progression unacceptable toxicity . Beginning 3 week completion chemotherapy , patient undergo involved-field radiotherapy . - Stratum 3 ( stage IIBE , IIIBE , IV ) : Male patient receive 2 course OEPA stratum 1 follow 4 course COPDIC stratum 2 . Female patient receive 2 course OPPA stratum 1 follow 4 course COPP stratum 2 . Beginning 3 week completion chemotherapy , patient undergo involved-field radiotherapy . PROJECTED ACCRUAL : A total 648 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis classic Hodgkin 's lymphoma ( HL ) Intermediate advance disease , include follow stage : Stage I Stage IIA , IIB , IIE , IIBE Stage IIIA IIIBE Stage IV PATIENT CHARACTERISTICS : No concurrent malignancies No severe concurrent disease ( e.g. , immune deficiency syndrome ) PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy Prephase therapy large mediastinal tumor allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
</DOC>